2023-509030-19-00CompletedPhase 1
A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to healthy adult participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Mar 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 25 Jan 2024
- Start date
- 18 Mar 2024
- Lead sponsor
- Janssen Cilag International
- EU CT number
- 2023-509030-19-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 36
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Janssen Pharmaceutica | Antwerp | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.